Soligenix Inc. (SNGX) 2.0200 $SNGX
Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Mon Aug 11, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014.
Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax(TM)
PR Newswire - Thu Aug 07, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). Previous studies had demonstrated that VeloThrax(TM) also possesses enhanced thermostability, enabling distribution without cold chain requirements.
Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield(TM) in GI ARS
PR Newswire - Fri Aug 01, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP). The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield(TM) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS). NIAID granted an initial award of $2.1 million to Soligenix on September 18, 2013. The total contract award is valued at up to $6.4 million over three years.
Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
PR Newswire - Wed Jul 09, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.
Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS
PR Newswire - Thu Sep 19, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $26.3 million by the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA). The contract is for the advanced preclinical and manufacturing development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Mon Aug 11, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014.
Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax(TM)
PR Newswire - Thu Aug 07, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). Previous studies had demonstrated that VeloThrax(TM) also possesses enhanced thermostability, enabling distribution without cold chain requirements.
Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield(TM) in GI ARS
PR Newswire - Fri Aug 01, 6:30AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP). The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield(TM) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS). NIAID granted an initial award of $2.1 million to Soligenix on September 18, 2013. The total contract award is valued at up to $6.4 million over three years.
Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
PR Newswire - Wed Jul 09, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the combination of RiVax(TM) and VeloThrax(TM) induces protective immunity to both ricin toxin and anthrax toxin exposure. RiVax(TM) is the Company's candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax(TM) is the Company's candidate vaccine that employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.
Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS
PR Newswire - Thu Sep 19, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $26.3 million by the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA). The contract is for the advanced preclinical and manufacturing development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
